Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase.
Organophosphorus acid anhydride (OP) "nerve agents" are rapid, stoichiometric, and essentially irreversible inhibitors of serine hydrolases. By placing a His near the oxyanion hole of human butyrylcholinesterase (BChE), we made an esterase (G117H) that catalyzed the hydrolysis of several OP, including sarin and VX [Millard et al. (1995) Biochemistry 34, 15925-15930]. G117H was limited, however, because it was irreversibly inhibited by pinacolyl methylphosphonofluoridate (soman); soman is among the most toxic synthetic poisons known. This limitation of G117H has been overcome by a new BChE (G117H/E197Q) that combines two engineered features: spontaneous dephosphonylation and slow aging (dealkylation). G117H/E197Q was compared with the single mutants BChE G117H and E197Q. Each retained cholinesterase activity with butyrylthiocholine as substrate, although kcat/Km decreased 11-, 11- or 110-fold for purified G117H, E197Q, or G117H/E197Q, respectively, as compared with wild-type BChE. Only G117H/E197Q catalyzed soman hydrolysis; all four soman stereoisomers as well as sarin and VX were substrates. Phosphonylation and dephosphonylation reactions were stereospecific. Double mutant thermodynamic cycles suggested that the effects of the His and Gln substitutions on phosphonylation were additive for PSCR or PRCR soman, but were cooperative for the PSCS stereoisomer. Dephosphonylation limited overall OP hydrolysis with apparent rate constants of 0.006, 0.077, and 0.128 min-1 for the PR/SCR, PSCS, and PRCS soman stereoisomers, respectively, at pH 7.5, 25 degrees C. We conclude that synergistic protein design converted an archetypal "irreversible inhibitor" into a slow substrate for the target enzyme.
Millard
C B
CB
United States Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland 21010-5425, USA. limill@weizmann.weizmann.ac.il
Lockridge
O
O
Broomfield
C A
CA
D019943:Amino Acid Substitution / Q000235:genetics; D000818:Animals; D043303:Aryldialkylphosphatase; D002091:Butyrylcholinesterase / Q000235:genetics / Q000378:metabolism*; D016466:CHO Cells; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D006224:Cricetinae; D004357:Drug Synergism; D004789:Enzyme Activation / Q000187:drug effects / Q000235:genetics; D004950:Esterases / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D016297:Mutagenesis, Site-Directed; D044345:Phosphoric Triester Hydrolases; D012999:Soman / Q000494:pharmacology; D013997:Time Factors
D002800:Cholinesterase Inhibitors; D012999:Soman; D004950:Esterases; D002091:Butyrylcholinesterase; D044345:Phosphoric Triester Hydrolases; D043303:Aryldialkylphosphatase; C020061:diisopropyl-fluorophosphatase